Featured Research

from universities, journals, and other organizations

Source of chlamydia reinfections may be GI tract

Date:
February 6, 2014
Source:
American Society for Microbiology
Summary:
The current standard of care treatment for chlamydia sometimes fails to eradicate the disease, according to a review, and the culprit may be in the gut.

The current standard of care treatment for chlamydia sometimes fails to eradicate the disease, according to a review published ahead of print in Infection and Immunity, and the culprit may be in the gut.

Chlamydia trachomatis not only infects the reproductive tract, but abides persistently -- though benignly -- in the gastrointestinal tract. There it remains even after eradication from the genitals by the antibiotic, azithromycin, says first author Roger Rank, of the Arkansas Children's Research Institute, Little Rock. And that reservoir is likely a source of the all-too-common reinfections that follow treatment.

The source of the reinfections has long been a conundrum. Some are blamed on continued intercourse with an infected partner. This is not surprising since chlamydia is usually asymptomatic in men.

Chlamydiae have long been assumed often to persist within the genital tract in a non-replicating form, but Rank says there is no evidence for this. "While all agree that chlamydiae may persist in a patient for long periods of time, and that recurrent infections do develop, there has been no agreement on how and where and in what form chlamydiae persist," says Rank.

In a recent study, coauthor and Arkansas colleague Laxmi Yeruva showed in mice that azithormycin eradicated the genital infection, but not the GI infection.

Rank showed further -- also in mice -- that chlamydial infection of the GI does not elicit an inflammatory response, and never resolves, unlike in the genital tract.

"However, we found that GI infection does produce a strong immune response that can actually be effective against a genital infection, but that is unable to cure the GI infection," says Rank.

While chlamydial persistence in the GI tract has largely escaped notice of late, it was documented in the veterinary literature in numerous animals as early as the 1950s, says Rank. His reading of that early literature was a major factor motivating his and Yeruva's studies, and this review, Rank says.

Chlamydia trachomatis is the most common cause of sexually transmitted disease in the world. In the US, approximately 1.4 million cases occur annually, according to the Centers for Disease Control and Prevention. Adolescents are most affected, and 6.8 percent of sexually active females ages 14-19 become infected annually.


Story Source:

The above story is based on materials provided by American Society for Microbiology. Note: Materials may be edited for content and length.


Journal Reference:

  1. R. G. Rank, L. Yeruva. "Hidden in plain sight:" Chlamydial gastrointestinal infection and its relevance to "persistence" in human genital infections. Infection and Immunity, 2014; DOI: 10.1128/IAI.01244-13

Cite This Page:

American Society for Microbiology. "Source of chlamydia reinfections may be GI tract." ScienceDaily. ScienceDaily, 6 February 2014. <www.sciencedaily.com/releases/2014/02/140206142127.htm>.
American Society for Microbiology. (2014, February 6). Source of chlamydia reinfections may be GI tract. ScienceDaily. Retrieved July 23, 2014 from www.sciencedaily.com/releases/2014/02/140206142127.htm
American Society for Microbiology. "Source of chlamydia reinfections may be GI tract." ScienceDaily. www.sciencedaily.com/releases/2014/02/140206142127.htm (accessed July 23, 2014).

Share This




More Health & Medicine News

Wednesday, July 23, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Courts Conflicted Over Healthcare Law

Courts Conflicted Over Healthcare Law

AP (July 22, 2014) Two federal appeals courts issued conflicting rulings Tuesday on the legality of the federally-run healthcare exchange that operates in 36 states. (July 22) Video provided by AP
Powered by NewsLook.com
Why Do People Believe We Only Use 10 Percent Of Our Brains?

Why Do People Believe We Only Use 10 Percent Of Our Brains?

Newsy (July 22, 2014) The new sci-fi thriller "Lucy" is making people question whether we really use all our brainpower. But, as scientists have insisted for years, we do. Video provided by Newsy
Powered by NewsLook.com
Scientists Find New Way To Make Human Platelets

Scientists Find New Way To Make Human Platelets

Newsy (July 22, 2014) Boston scientists have discovered a new way to create fully functioning human platelets using a bioreactor and human stem cells. Video provided by Newsy
Powered by NewsLook.com
Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

TheStreet (July 21, 2014) New research shows Gilead Science's drug Sovaldi helps in curing hepatitis C in those who suffer from HIV. In a medical study, the combination of Gilead's Hep C drug with anti-viral drug Ribavirin cured 76% of HIV-positive patients suffering from the most common hepatitis C strain. Hepatitis C and related complications have been a top cause of death in HIV-positive patients. Typical medication used to treat the disease, including interferon proteins, tended to react badly with HIV drugs. However, Sovaldi's %1,000-a-pill price tag could limit the number of patients able to access the treatment. TheStreet's Keris Lahiff reports from New York. Video provided by TheStreet
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins